Immunology and inflammation

News

Lab-in-a-loop specialist Relation attracts Novartis alliance

UK-based AI and multi-omics company Relation Therapeutics will seek out targets for allergic diseases on behalf of Novartis in a $1.7bn-plus alliance.

News

Amgen, AZ's Tezspire challenges Dupixent in nasal polyps

Amgen and AstraZeneca's fast-growing asthma drug Tezspire is now poised to take on rival Dupixent in chronic rhinosinusitis with nasal polyps.

News

MSD advances on a broad front with TL1A drug tulisokibart

MSD's confidence in its anti-TL1A drug tulisokibart in inflammatory diseases is made apparent by a decision to start trials in three new indications.

News

FDA clears Novartis' oral drug for chronic hives

Novartis has claimed a first-in-class approval in the US for its oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria.

News

Novartis agrees $5.7bn degrader deal with Monte Rosa

Novartis has signed its second multibillion-dollar licensing deal with molecular glue degrader specialist Monte Rosa in less than a year.

News

Sanofi slumps despite positive eczema drug readout

Shares in Sanofi have fallen after it reported data from a phase 3 trial of atopic dermatitis drug amlitelimab – even though it met all objectives.

Lab-in-a-loop specialist Relation attracts Novartis alliance

Amgen, AZ's Tezspire challenges Dupixent in nasal polyps

MSD advances on a broad front with TL1A drug tulisokibart

FDA clears Novartis' oral drug for chronic hives

Novartis agrees $5.7bn degrader deal with Monte Rosa

Sanofi slumps despite positive eczema drug readout

Padcev/Keytruda scores again in early bladder cancer

How to meet your physicians where they are online

Immunology and inflammation

Editor's Picks